| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | -100.0% |
| R&D Expense | $12.4M | — | +140.2% |
| SG&A Expense | $4.6M | — | +23.1% |
| Operating Income | -$16.9M | — | -96.7% |
| Net Income | -$21.3M | — | -295.1% |
| EPS (Basic) | -$0.42 | — | -281.8% |
| EPS (Diluted) | -$0.42 | — | -281.8% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $36.7M | +72.5% | +428.2% |
| Short-term Investments | $22.6M | +20.3% | -32.9% |
| Current Assets | $62.7M | +55.3% | +20.0% |
| Total Assets | $77.6M | +31.5% | +14.3% |
| Current Liabilities | $15.9M | +177.3% | +77.5% |
| Total Liabilities | $36.3M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$8.1M | — | -8.5% |
| Investing Cash Flow | -$525K | — | -104.2% |
| Financing Cash Flow | $24.0M | — | +270.7% |
| +108.9% |
| Stockholders' Equity | $41.3M | -16.3% | -18.3% |